A new antibody treatment called Ccombody significantly boosted immune responses in Pacific white shrimp infected with AHPND, a deadly bacterial disease. According to Gram Research analysis of this 2026 study, shrimp fed diets containing Ccombody showed substantially higher expression of protective immune genes within 24 hours of infection and improved survival rates compared to untreated shrimp. This suggests antibody-based prevention could replace antibiotics in shrimp farming, addressing growing concerns about antibiotic resistance.
Researchers tested a new type of antibody called Ccombody to protect Pacific white shrimp from a serious bacterial disease called AHPND. The disease kills shrimp by damaging their digestive organs and is caused by bacteria that produce harmful toxins. In this study, shrimp fed diets containing Ccombody showed stronger immune responses and better survival rates when exposed to the disease compared to shrimp that didn’t receive the treatment. This research suggests that using antibodies as a preventive strategy could help shrimp farmers protect their crops without relying on antibiotics, which are becoming less effective due to overuse.
Key Statistics
A 2026 research article found that Pacific white shrimp fed Ccombody-supplemented diets showed significantly higher expression of the proPO-2 immune gene at 24 hours post-infection compared to control groups, with dose-dependent improvements at 1, 10, and 100 mg/100 g feed levels.
Shrimp receiving the highest dose of Ccombody (100 mg/100 g feed) demonstrated improved survival rates after AHPND infection compared to both untreated controls and shrimp receiving an existing IgY antibody treatment, suggesting superior efficacy of the new antibody approach.
In this controlled laboratory study of Pacific white shrimp, Ccombody treatment activated immune responses within 24 hours of bacterial infection, indicating rapid protective action against the AHPND pathogen that produces PirA and PirB toxins.
The Quick Take
- What they studied: Whether a new antibody treatment called Ccombody could protect shrimp from a deadly bacterial disease and boost their immune system
- Who participated: Pacific white shrimp divided into six groups, with each group tested in triplicate (three separate tanks). Groups received either no treatment, a standard diet, an existing antibody treatment, or Ccombody at different dose levels
- Key finding: Shrimp receiving Ccombody showed significantly higher expression of immune-fighting genes 24 hours after infection, and survival rates improved with higher doses of the treatment
- What it means for you: If you raise shrimp commercially, this research suggests a new way to prevent disease without antibiotics. However, this is early-stage research, and more testing in larger populations is needed before widespread use
The Research Details
Scientists divided Pacific white shrimp into six different groups and fed them different diets for one week. Some shrimp ate normal food, some ate food mixed with an existing antibody treatment called IgY, and others ate food containing Ccombody at three different amounts (1, 10, or 100 milligrams per 100 grams of feed). After one week of feeding, the researchers infected the shrimp with the AHPND bacteria and measured what happened.
The researchers looked at three specific immune genes that help shrimp fight infections: proPO-2, ALF-1, and PEN4. They measured how active these genes were at different time points after infection. They also tracked how many shrimp survived the infection in each group.
This experimental design allowed researchers to compare how well Ccombody worked at different doses compared to no treatment and compared to an existing antibody treatment. By using multiple groups and repeating each group three times, they could see if their results were consistent and reliable.
This research approach is important because it tests a completely new strategy for preventing shrimp disease. Instead of using antibiotics that bacteria are becoming resistant to, this study explores using antibodies (immune proteins) that target the specific toxins causing the disease. By measuring gene expression, researchers can see exactly how the immune system responds at the molecular level, not just whether shrimp survive or die
The study used a proper control design with both negative controls (healthy shrimp) and positive controls (infected shrimp without treatment), which is the gold standard for testing new treatments. Each group was tested in triplicate, meaning the experiment was repeated three times to ensure results were consistent. However, the sample size appears relatively small, which is typical for preliminary laboratory studies. The research was published in a peer-reviewed journal, meaning other experts reviewed it before publication. This is early-stage research, so results need confirmation in larger studies before practical application
What the Results Show
Before infection, shrimp in all groups showed similar levels of immune gene activity, suggesting that Ccombody didn’t activate the immune system just from being in the diet. However, after the shrimp were infected with AHPND bacteria, the results changed dramatically.
At 24 hours after infection, shrimp that had eaten Ccombody showed significantly higher expression of the proPO-2 immune gene compared to both the control groups. This gene is crucial for fighting bacterial infections in shrimp. The effect was dose-dependent, meaning that shrimp receiving higher amounts of Ccombody showed stronger immune responses.
Survival rates also improved with Ccombody treatment. Shrimp in the highest-dose Ccombody group (100 mg/100 g feed) showed the best survival rates after infection. The reference group receiving the existing IgY antibody treatment showed some improvement over untreated controls, but Ccombody appeared more effective.
The other two immune genes measured (ALF-1 and PEN4) showed similar patterns, with Ccombody-treated shrimp mounting stronger immune responses than controls, though these differences were less pronounced than the proPO-2 results.
The research revealed that the timing of immune response matters significantly. The strongest immune activation occurred at 24 hours after infection, suggesting this is a critical window when Ccombody provides maximum protection. The dose-response relationship (higher doses producing stronger effects) is important because it suggests the treatment works in a predictable, measurable way. The fact that Ccombody outperformed the existing IgY antibody treatment suggests this new approach may be more effective than current alternatives
Previous research has shown that antibiotics are becoming less effective against AHPND because bacteria develop resistance. This study builds on earlier work showing that antibodies can target specific bacterial toxins. The use of recombinant antibodies (artificially created in laboratories) is a newer approach compared to traditional antibiotics. This research aligns with a growing trend in aquaculture to use immunological strategies rather than chemical treatments, similar to how vaccines work in human medicine
The study used a relatively small number of shrimp, which is typical for preliminary research but limits how confidently we can apply results to large commercial farms. The research was conducted in controlled laboratory conditions, which may not perfectly reflect real-world farm environments where shrimp face multiple stressors. The study only tested one disease (AHPND) in one species of shrimp (Pacific white shrimp), so results may not apply to other shrimp species or other diseases. The long-term effects of Ccombody treatment were not studied, so we don’t know if protection lasts beyond the initial infection period. Additionally, the cost-effectiveness of this treatment compared to other prevention methods was not evaluated
The Bottom Line
Based on this research, Ccombody shows strong promise as a disease prevention strategy for Pacific white shrimp farms. The evidence suggests using dietary supplementation at higher doses (closer to 100 mg/100 g feed) produces the best immune response. However, this is preliminary research, and farmers should wait for larger-scale studies and cost-benefit analyses before implementing this treatment commercially. The recommendation level is moderate to strong for research purposes, but not yet ready for widespread commercial adoption without further validation
Shrimp farmers and aquaculture companies should pay attention to this research, especially those struggling with AHPND outbreaks or antibiotic resistance. Researchers studying disease prevention in aquaculture should find this work relevant. Pet shrimp keepers may eventually benefit if this treatment becomes commercially available. People concerned about antibiotic resistance in food production should find this research encouraging. However, consumers buying shrimp at grocery stores don’t need to change their behavior based on this single study
Based on the study results, immune protection appears within 24 hours of infection, suggesting relatively quick action. However, the shrimp were fed Ccombody for 7 days before infection, so the treatment requires advance preparation. In a real farm setting, farmers would need to add Ccombody to feed several days before disease exposure. Long-term protection duration is unknown and requires further research. Realistic expectations for commercial availability would be 3 to 5 years of additional testing and regulatory approval
Frequently Asked Questions
What is AHPND and why is it a problem for shrimp farming?
AHPND is a bacterial disease caused by Vibrio parahaemolyticus that produces toxins destroying shrimp digestive organs. It causes mass die-offs in shrimp farms and is difficult to treat with antibiotics because bacteria develop resistance to these drugs over time.
How does Ccombody work differently than antibiotics?
Ccombody is an antibody that specifically targets the PirA toxin produced by the AHPND bacteria, neutralizing it before it damages shrimp cells. Unlike antibiotics that kill bacteria, Ccombody blocks the toxin’s harmful effects, reducing the chance bacteria develop resistance.
When can shrimp farmers start using Ccombody to prevent disease?
This is preliminary research, so Ccombody is not yet available for commercial use. Farmers should expect 3 to 5 years of additional testing and regulatory approval before this treatment becomes widely available for farm use.
Does Ccombody work for other types of shrimp or other diseases?
This study only tested Pacific white shrimp against AHPND. Whether Ccombody works for other shrimp species or other diseases is unknown and would require separate research studies to determine.
Is Ccombody treatment expensive compared to antibiotics?
The study did not evaluate cost or compare expenses to antibiotics. Cost-effectiveness analysis would be necessary before farmers could make practical decisions about adopting this treatment on commercial farms.
Want to Apply This Research?
- If you manage a shrimp farm, track daily mortality rates and compare them week-by-week before and after implementing Ccombody supplementation. Record the exact dose used and feed consumption rates to correlate with health outcomes
- Shrimp farm managers could implement a preventive feeding protocol where Ccombody-supplemented feed is introduced 7 to 10 days before anticipated disease risk periods (such as seasonal transitions or after introducing new stock)
- Establish a baseline of normal mortality rates for your farm, then monitor for changes after implementing Ccombody. Track water quality parameters, feed consumption, and any visible signs of disease. Compare your results to previous years to assess whether the treatment is working in your specific conditions
This research describes laboratory findings in shrimp and represents early-stage investigation into a potential disease prevention strategy. Ccombody is not currently approved for commercial use in shrimp farming. Results from controlled laboratory studies may not directly translate to real-world farm conditions with multiple environmental variables. Shrimp farmers should consult with aquaculture specialists and regulatory agencies before implementing any new disease prevention strategies. This article is for informational purposes and should not be considered medical or veterinary advice. Always follow local regulations and guidelines for shrimp farming practices.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.